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Abstract 
Gestational diabetes is a concern for a large number of pregnant 
women due to the potential for long-term complications for both the 
mother and the fetus. With the increasing prevalence of obesity and 
diabetes in the general public, the number of pregnant women with 
undiagnosed type 2 diabetes mellitus has also increased. In order 
to adequately educate their patients, it is important for pharmacists 
to be aware of the general practices of treating gestational diabetes. 
This review will highlight recent updates to initial screening, the 
criteria for diagnosing gestational diabetes, and current manage-
ment strategies. 
Introduction 
Any onset of glucose intolerance that manifests during pregnancy, 
without previously recognized type 2 diabetes mellitus (T2DM) risk fac-
tors, is classified as gestational diabetes mellitus (GDM).1 Gestational 
diabetes is a concern for expectant mothers, affecting up to 7 percent of 
all pregnancies. GDM can lead to maternal and/or fetal complications. 
Women with this condition are at risk for pre-eclampsia, cesarean sec-
tion and postpartum T2DM, while the fetus may be at risk of macrosomia 
(increased birth weight), higher fetal adiposity and abnormal glucose 
tolerance. 2·5 
Previous guidelines only addressed diagnosis in women who experience 
hyperglycemia during pregnancy; they did not attempt to determine if 
the diabetes was pre-existing. As a result of the increased concern of 
missing pre-existing diabetes, American Diabetes Association (ADA) 
guidelines dictate that women with risk factors for T2DM be screened 
at their first prenatal visit using the standard diagnostic criteria shown in 
Table 1. If unequivocal hyperglycemia is not present, the results should 
be confirmed by repeat testing. If detection of diabetes is made at the 
initial screening of a patient with risk factors, a diagnosis of overt, not 
gestational, diabetes should be made.6•7 
Table 1: Criteria for the diagnosis of diabetes6 
Women must present with one of the following criteria: 
• Hemoglobin A1C (HbA1C) ~ 6.5% 
• Fasting plasma glucose (FPG) ~ 126 mg/di 
• 2 hour plasma glucose ~ 200 mg/di during an oral glucose tol-
erance test (OGTI) performed using a glucose load containing 
the equivalent of 75 g anhydrous glucose dissolved in water 
• A random plasma glucose~ 200 mg/di in a patient with classic 
symptoms of hyperglycemia or hyperglycemic crisis 
Diagnosis 
Women with the risk factors listed in Table 2 should be screened at their 
first prenatal visit using the standard diagnostic criteria for diabetes (Table 
1 ).6 Pregnant women who are not diabetic and do not display risk factors 
for diabetes should be screened for GDM at 24-28 weeks of gestation 
using a 75 g two-hour OGTI. Diagnosis is made from the OGTI upon 
exceeding any of the following plasma glucose values: fasting ~ 92 mg/di, 
1 hour ~ 180 mg/di or 2 hour ~ 153 mg/di. Based on the new recommenda-
tions, only one abnormal value, as opposed to two, is necessary to make 
the diagnosis; thus, the prevalence of GDM will likely rise. This change in 
diagnostic practices has been made with the hope of optimizing gestational 
outcomes. 
Table 2: Criteria for testing for diabetes In asymptomatic adult 
individuals6 
1. Testing should be considered in all adults who are overweight 
(body mass index or BMI ~ 25 kg/m2*) and have additional risk factors: 
• Physical inactivity 
• First-degree relative with diabetes 
• High-risk race/ethnicity (e.g., African American, Latino, Native 
American, Asian American, Pacific Islander) 
• Women who delivered a baby weighing > 9 lb or were diagnosed 
with GDM 
• Hypertension(~ 140/90 mmHg or on therapy for hypertension) 
• HDL cholesterol level< 35 mg/di and/or a triglyceride level> 250 mg/di 
• Women with polycystic ovarian syndrome 
• HbA 1C~5.7%, impaired glucose tolerance (IGT) or impaired fast-
ing glucose (IFG) on previous testing 
• Other clinical conditions associated with insulin resistance (e.g., 
severe obesity, acanthosis nigricans) 
• History of cardiovascular disease 
2. In the absence of the above criteria, testing for diabetes should 
begin at age 45. 
3. If results are normal, testing should be repeated at a minimum 
of three-year intervals, with consideration of more frequent testing 
depending on initial results and risk status. 
*At-risk BMI may be lower in some ethnic groups. 
Fetal Complications 
Gestational diabetes can cause both short-term and long-term fetal com-
plications.8 Women with gestational diabetes have an increased resistance 
to insulin, which alters the uptake of glucose into tissues and decreases 
the suppression of lipolysis and protein synthesis. These alterations 
increase the mother's blood glucose, making more available to the fetus, 
thereby providing more nutrition to the fetus for growth. As a result, the 
concentration of glucose in the fetal blood will rise and cause the fetus to 
35 The Pharmacy and Wellness Review Volume two, Issue two May 2011 
An Update on Gestational Diabetes Endocrinology 
secrete more than his or her basal level of insulin. When the baby is born 
and the umbilical cord is cut, the fetal pancreas will continue to produce 
excess insulin, and the baby will most likely present with lethargy and 
hypoglycemia from this large amount of insulin. The surplus of glucose 
delivered to the fetus may lead to macrosomia, high fetal adiposity and 
birth trauma. Babies born with high birth weight are at risk of shoulder 
dystocia and other traumas during birth due to their large size.9 High birth 
weight puts the infant at risk of developing adolescent obesity, which can 
further lead to obesity as an adult. 10 As a result of the obesity, diabetes 
and cardiovascular disease may also develop later in life. The fetuses of 
women with undiagnosed glucose intolerance prior to pregnancy are at an 
even greater risk of acquiring excess adipose tissue. 
Prevention 
There are many different modifiable and nonmodifiable risk factors for 
GDM. Modifiable risk factors include being overweight or obese and 
physical inactivity, while ethnicity, race, family history of GDM, and age 
are nonmodifiable risk factors. Obese women have been reported to 
have a 17 percent increased risk of developing GDM. Overweight wom-
en with a BMI of 25-30 kg/m2 are 1.8 to 6.5 times more likely to develop 
GDM when compared to normal weight women.8 Lifestyle modifications 
to help decrease a woman's weight and incorporate more physical activ-
ity can help decrease the risk for developing GDM. Dietary education 
and recommendations can help women at risk of GDM decrease their 
calorie intake to help reduce their weight. Dietary restrictions will help 
keep the woman's glucose levels and HbA 1 C within normal limits and 
can help prevent the onset of insulin resistance. 
Lack of physical activity is a risk factor for both obesity and T2DM. Since 
60 percent of women with GDM develop T2DM, increased physical activity 
as a lifestyle modification can have many health benefits.8 Women with 
regular physical activity prior to becoming pregnant have been shown to 
have less chance of developing GDM. A self-reported questionnaire study 
conducted by Dempsey compared the effects of physical activity between 
two groups of women: active during pregnancy and inactive during preg-
nancy. This study showed a 48 percent reduction of GDM in women with . 
the most activity during the first 20 weeks of their pregnancy. Risk for GDM 
was reduced by 51 percent in women with the most activity one year prior 
to the studied pregnancy. According to the authors, these two findings 
show a combined 60 percent reduction in risk for GDM. However, due to a 
lack of well-controlled studies, no exercise guidelines can be established. 11 
Treatment 
All women diagnosed with GDM should receive nutritional counseling by 
a registered dietitian whenever possible. 1 The medical nutrition therapy 
(MNT) should be individualized based upon maternal weight and height. The 
MNT should allow for adequate calories and nutrients to meet the needs of 
pregnancy and to be consistent with the established maternal blood glucose 
goals. Pharmacological treatment is warranted when maternal glucose levels 
are not controlled by diet and lifestyle modification alone. 
Historically, insulin has been the pharmacologic therapy most consistently 
shown to reduce fetal morbidities when added to MNT.1 When insulin is 
prescribed, the dosing and timing should be based upon self-monitored 
blood glucose levels. The disadvantages of insulin for the mother include 
the complexity of administering a subcutaneous injection, risks of hypogly-
cemia and increased appetite and weight gain. The ADA guidelines do not 
recommend the use of insulin analogs for treating GDM; however, there 
have been studies reporting safe and effective use of both rapid-acting 
(lispro) and intermediate-acting insulin (NPH).12.13 Insulin lispro has actually 
been reported to be more efficacious than human regular insulin to nor-
malize the blood glucose levels in GDM by lowering postprandial glucose 
levels and HbA1C levels with fewer hypoglycemic episodes. 12•14 In a large 
clinical trial (n=213 GDM patients) comparing lispro and regular insulin, 
there were no significant differences in maternal or fetal outcomes. Ad-
ditionally, the lispro arm had lower predelivery HbA 1 C values and higher 
patient satisfaction compared to the regular insulin arm.15 
None of the oral glucose-lowering agents have FDA approval for the 
treatment of GDM.1 However, metformin and glyburide have both been 
utilized and studied for GDM over the last two decades. Oral agents 
are less expensive and complicated to administer than insulin. Addi-
tionally, side effects of hypoglycemia and weight gain may be avoided 
or lessened. Glyburide, or the sulfonylureas in general, are beta cell 
stimulators, which increase the release of endogenous insulin into the 
blood stream. Therefore, hypoglycemia and weight gain are potential 
side effects of these medications. Metformin works primarily by increas-
ing receptor sensitivity to insulin as well as decreasing excessive hepatic 
glycogenolysis. Metformin is not associated with weight gain or hypogly-
cemia and may actually cause some weight loss. 16·17 
Metformin appears to be a logical option for women with GDM as it 
improves insulin sensitivity and is not associated with hypoglycemia or 
weight gain. Its use in GDM is considered to be unlabeled or investiga-
tional.17 Metformin crosses the placenta, and so it may consequently af-
fect fetal physiology directly; thus, it is classified as FDA pregnancy risk 
category Band is not recommended for routine use in pregnancy.13·16·17 
However, according to Briggs' Drugs in Pregnancy and Lactation, there 
is no evidence of adverse fetal effects. 18 A study published in The New 
England Journal of Medicine in 2008 examined the use of metformin 
compared to insulin in the treatment of GDM.13 The participants were 
started at a metformin dose of 500 mg once or twice daily with food and 
increased, typically over a period of one to two weeks to meet glycemic 
targets, up to a maximum daily dose of 2,500 mg. The rates of neonatal 
hypoglycemia were similar in the metformin and insulin study groups, but 
severe hypoglycemia occurred significantly less often in infants whose 
mothers were taking metformin. There was a higher frequency of pre-
term births in the metformin group, which may have been due to chance 
or unrecognized effects of metformin use. However, the difference 
between the two study groups in mean gestational age at delivery was 
of no clinical significance. In the study, 46.3 percent of the women in the 
metformin arm required supplemental insulin. The authors concluded 
that there was no difference between treatments with metformin as com-
pared to insulin. The study's findings support the use of metformin alone 
or with supplemental insulin as a safe and effective treatment option for 
women diagnosed with GDM. The insulin protocol employed in the study 
was a short-acting insulin analog before meals and an intermediate 
insulin once or twice daily .13 
A recent review article on the use of glyburide for GDM examined ran-
domized prospective trials, prospective studies and cohort studies with a 
total of more than 1,000 patients. The studies demonstrate that glyburide 
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is as well tolerated, as safe and as useful as insulin for the treatment 
of GDM. Although, the author suggested that glyburide may become 
the drug of choice for the treatment of GDM, glyburide's use in GDM is 
considered to be unlabeled or investigational as it is classified as FDA 
pregnancy risk category B or C depending on the manufacturer. 19•20•21 
Minimal amounts of glyburide have been detected crossing the placenta 
in an in vitro perfusion model.22 According to Briggs' Drugs in Pregnancy 
and Lactation, neonatal hypoglycemia secondary to glyburide appears to 
be a low risk.18To date, there have not been any trials comparing metfor-
min use to that of glyburide as far as the authors are aware. Therefore, 
before GDM can become a labeled indication of metformin and gly-
buride, randomized controlled trials should be completed to compare the 
two oral glucose-lowering agents to determine the medication of choice 
for GDM patients. 
Role of the Pharmacist 
Gestational diabetes is a concern for a large number of pregnant 
women, and with the recent changes in diagnostic guidelines, it will 
become more prevalent in the years to come. To help with the predicted 
rise, pharmacists can play an active role in the prevention, monitoring 
and treatment of GDM.6 Many risk factors for GDM, such as increased 
weight and physical inactivity, can readily be improved by patient educa-
tion. Pharmacists in both community and clinical settings can educate 
their pregnant patients on the benefits of maintaining a healthy weight 
and incorporating exercise into their daily routines. In addition to educat-
ing, the pharmacist can continually motivate patients to incorporate 
these healthy behaviors into their lives once they become pregnant. 
GDM can usually be managed with lifestyle modifications, but in some cases 
pharmacologic therapy is required. In these cases, the pharmacist is a valu-
able resource to counsel the patient on the proper use, storage and possible 
side effects of the drugs. Proper insulin administration techniques should 
be explained and demonstrated to patients. The pharmacist is also an 
imperative resource on appropriate technique and the use of blood glucose 
monitoring supplies. Monitoring blood glucose is essential to optimizing the 
effectiveness of all medications used for GDM. The pharmacist's role in 
education, prevention and disease state management in patients with GDM 
is vital to improve the health outcomes of both mother and child. 
Conclusion 
GDM affects up to 7 percent of all pregnancies and has the potential 
to cause complications for both the mother and the fetus. Due to the 
updates to the ADA guidelines for diagnosis of GDM, affected mothers 
will now be able to receive treatment earlier in pregnancy in order to 
avoid complications. Although the ADA only endorses the use of regular 
insulin for the management of GDM, numerous studies have employed 
short- and long-acting insulin analogs as well as oral glucose-lowering 
agents. It is important for pharmacists to understand the changes in 
diagnostic criteria and treatment options in order to effectively educate 
and treat their patients. 
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